Log in

NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News

+0.05 (+1.36 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $3.72
50-Day Range N/A
52-Week Range
Now: $3.72
Volume251,500 shs
Average Volume189,785 shs
Market Capitalization$120.68 million
P/E RatioN/A
Dividend YieldN/A
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.
Read More
Protalix Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNYSEMKT:PLX



Sales & Book Value

Annual SalesN/A



Market Cap$120.68 million
Next Earnings Date11/5/2020 (Estimated)
+0.05 (+1.36 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protalix Biotherapeutics

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Protalix Biotherapeutics

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.08. During the same quarter in the prior year, the business posted ($0.50) earnings per share.
View Protalix Biotherapeutics' earnings history

When did Protalix Biotherapeutics' stock split? How did Protalix Biotherapeutics' stock split work?

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PLX?

1 brokerages have issued 12-month target prices for Protalix Biotherapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Protalix Biotherapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 195.7% from the stock's current price.
View analysts' price targets for Protalix Biotherapeutics

Has Protalix Biotherapeutics been receiving favorable news coverage?

Headlines about PLX stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about Protalix Biotherapeutics

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 195,800 shares, a decline of 84.5% from the April 30th total of 1,260,000 shares. Based on an average daily volume of 200,300 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.8% of the shares of the company are short sold.
View Protalix Biotherapeutics' Short Interest

Who are some of Protalix Biotherapeutics' key competitors?

What other stocks do shareholders of Protalix Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BIOLINERX LTD/S (BLRX), VBI Vaccines (VBIV), Verastem (VSTM), Sangamo Therapeutics (SGMO), Biopharmx (BPMX), Opko Health (OPK) and Crispr Therapeutics (CRSP).

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the following people:
  • Mr. Moshe Manor, CEO, Pres & Director (Age 63)
  • Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
  • Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 55)
  • Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Psagot Investment House Ltd. (1.45%), Phoenix Holdings Ltd. (0.58%) and Bank of Montreal Can (0.54%).
View institutional ownership trends for Protalix Biotherapeutics

Which major investors are buying Protalix Biotherapeutics stock?

PLX stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Bank of Montreal Can, and Psagot Investment House Ltd..
View insider buying and selling activity for Protalix Biotherapeutics

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $3.72.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $120.68 million. Protalix Biotherapeutics employs 184 workers across the globe.

What is Protalix Biotherapeutics' official website?

The official website for Protalix Biotherapeutics is www.protalix.com.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.